Cargando…
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin’s lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was o...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710959/ https://www.ncbi.nlm.nih.gov/pubmed/29207679 http://dx.doi.org/10.18632/oncotarget.18114 |
_version_ | 1783282979345268736 |
---|---|
author | Pellegrini, Cinzia Broccoli, Alessandro Pulsoni, Alessandro Rigacci, Luigi Patti, Caterina Gini, Guido Mannina, Donato Tani, Monica Rusconi, Chiara Romano, Alessandra Vanazzi, Anna Botto, Barbara Santoro, Armando Hoaus, Stefan Rigolin, Gian Matteo Musto, Pellegrino Mazza, Patrizio Molica, Stefano Corradini, Paolo Fama, Angelo Gaudio, Francesco Merli, Michele Ronconi, Fioravante Gritti, Giuseppe Vallisa, Daniele Tosi, Patrizia Liberati, Anna Marina Pinto, Antonello Pavone, Vincenzo Gherlinzoni, Filippo Bianchi, Maria Paola Volpetti, Stefano Trentin, Livio Goldaniga, Maria Cecilia Bonfichi, Maurizio De Renzo, Amalia Schiavotto, Corrado Spina, Michele Carella, Angelo Michele Stefoni, Vittorio Argnani, Lisa Zinzani, Pier Luigi |
author_facet | Pellegrini, Cinzia Broccoli, Alessandro Pulsoni, Alessandro Rigacci, Luigi Patti, Caterina Gini, Guido Mannina, Donato Tani, Monica Rusconi, Chiara Romano, Alessandra Vanazzi, Anna Botto, Barbara Santoro, Armando Hoaus, Stefan Rigolin, Gian Matteo Musto, Pellegrino Mazza, Patrizio Molica, Stefano Corradini, Paolo Fama, Angelo Gaudio, Francesco Merli, Michele Ronconi, Fioravante Gritti, Giuseppe Vallisa, Daniele Tosi, Patrizia Liberati, Anna Marina Pinto, Antonello Pavone, Vincenzo Gherlinzoni, Filippo Bianchi, Maria Paola Volpetti, Stefano Trentin, Livio Goldaniga, Maria Cecilia Bonfichi, Maurizio De Renzo, Amalia Schiavotto, Corrado Spina, Michele Carella, Angelo Michele Stefoni, Vittorio Argnani, Lisa Zinzani, Pier Luigi |
author_sort | Pellegrini, Cinzia |
collection | PubMed |
description | A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin’s lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients. |
format | Online Article Text |
id | pubmed-5710959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57109592017-12-04 Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma Pellegrini, Cinzia Broccoli, Alessandro Pulsoni, Alessandro Rigacci, Luigi Patti, Caterina Gini, Guido Mannina, Donato Tani, Monica Rusconi, Chiara Romano, Alessandra Vanazzi, Anna Botto, Barbara Santoro, Armando Hoaus, Stefan Rigolin, Gian Matteo Musto, Pellegrino Mazza, Patrizio Molica, Stefano Corradini, Paolo Fama, Angelo Gaudio, Francesco Merli, Michele Ronconi, Fioravante Gritti, Giuseppe Vallisa, Daniele Tosi, Patrizia Liberati, Anna Marina Pinto, Antonello Pavone, Vincenzo Gherlinzoni, Filippo Bianchi, Maria Paola Volpetti, Stefano Trentin, Livio Goldaniga, Maria Cecilia Bonfichi, Maurizio De Renzo, Amalia Schiavotto, Corrado Spina, Michele Carella, Angelo Michele Stefoni, Vittorio Argnani, Lisa Zinzani, Pier Luigi Oncotarget Clinical Research Paper A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin’s lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients. Impact Journals LLC 2017-05-23 /pmc/articles/PMC5710959/ /pubmed/29207679 http://dx.doi.org/10.18632/oncotarget.18114 Text en Copyright: © 2017 Pellegrini et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Pellegrini, Cinzia Broccoli, Alessandro Pulsoni, Alessandro Rigacci, Luigi Patti, Caterina Gini, Guido Mannina, Donato Tani, Monica Rusconi, Chiara Romano, Alessandra Vanazzi, Anna Botto, Barbara Santoro, Armando Hoaus, Stefan Rigolin, Gian Matteo Musto, Pellegrino Mazza, Patrizio Molica, Stefano Corradini, Paolo Fama, Angelo Gaudio, Francesco Merli, Michele Ronconi, Fioravante Gritti, Giuseppe Vallisa, Daniele Tosi, Patrizia Liberati, Anna Marina Pinto, Antonello Pavone, Vincenzo Gherlinzoni, Filippo Bianchi, Maria Paola Volpetti, Stefano Trentin, Livio Goldaniga, Maria Cecilia Bonfichi, Maurizio De Renzo, Amalia Schiavotto, Corrado Spina, Michele Carella, Angelo Michele Stefoni, Vittorio Argnani, Lisa Zinzani, Pier Luigi Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma |
title | Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma |
title_full | Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma |
title_fullStr | Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma |
title_full_unstemmed | Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma |
title_short | Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma |
title_sort | italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory hodgkin’s lymphoma |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710959/ https://www.ncbi.nlm.nih.gov/pubmed/29207679 http://dx.doi.org/10.18632/oncotarget.18114 |
work_keys_str_mv | AT pellegrinicinzia italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT broccolialessandro italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT pulsonialessandro italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT rigacciluigi italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT patticaterina italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT giniguido italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT manninadonato italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT tanimonica italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT rusconichiara italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT romanoalessandra italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT vanazzianna italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT bottobarbara italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT santoroarmando italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT hoausstefan italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT rigolingianmatteo italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT mustopellegrino italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT mazzapatrizio italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT molicastefano italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT corradinipaolo italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT famaangelo italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT gaudiofrancesco italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT merlimichele italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT ronconifioravante italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT grittigiuseppe italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT vallisadaniele italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT tosipatrizia italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT liberatiannamarina italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT pintoantonello italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT pavonevincenzo italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT gherlinzonifilippo italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT bianchimariapaola italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT volpettistefano italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT trentinlivio italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT goldanigamariacecilia italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT bonfichimaurizio italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT derenzoamalia italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT schiavottocorrado italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT spinamichele italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT carellaangelomichele italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT stefonivittorio italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT argnanilisa italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma AT zinzanipierluigi italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma |